We aimed to examine whether targeting DDX11 by small interfering RNA (siRNA) affects cell viability in ovarian cancer cell lines exposed to baseline therapy constituted by cisplatin and olaparib, as previous results suggested a role for vertebrate DDX11 in the tolerance of such lesions (17, 18, 23). Here, DDX11 is linked to ovarian carcinoma.